Abstract:Abstract BACKGROUND AND AIMS Sarcopenia is common in chronic kidney disease (CKD) and is associated with increased mortality and morbidity. Sarcopenia in CKD can be defined as a decreased muscle mass, mainly due to the catabolic state caused by the uremic environment. Malnutrition and inflammation are also common in sarcopenic patients. In this study, we aimed to investigate the prevalence of sarcopenia defined as low muscle mass determined by Psoas Muscle Index (PMI) in waitlisted end-stage renal disease (ESRD) patients and its association between ‘Prognostic Nutritional Index (PNI)’, ‘C-reactive protein (CRP) to Albumin Ratio (CAR)’ and mortality. METHOD ESRD patients registered to national kidney transplant waiting list and had abdomen CT at admission were included in the study. Kidney donor candidates were constituted as healthy controls. PMI (cm2/m2) were calculated by proportioning the psoas muscle area detected in the abdomen CT with the square of the height. The PMI of the controls at the fifth percentile according to gender was accepted as the limit value for sarcopenia. PNI and CAR were calculated using albumin, CRP and absolute lymphocyte count. The associations between PMI, PNI, CAR and all-cause mortality were investigated. RESULTS A total of 162 ESRD patients and 87 age matched healthy controls were included in the study. The mean age of the patients was 44.7 ± 14.2 years and follow-up time was 3.37 (0.35–9.60) years. The mean PMI were similar between the groups (5.24 ± 1.71 versus 5.48 ± 1.87 cm2/m2 P = 0.302). While prevalence of sarcopenia (16.7% versus 3.4%, P = 0.002) and CAR [1.47 (0.12–37.10) versus 0.74 (0.21–10.20), P < 0.001] was higher; PNI [40 (20.4–52.2) versus 44 (36.1–53.0), P < 0.001] was lower in ESRD patients than controls. When ESRD patients compared according to sarcopenia PMI [3.45 ± 0.9 versus 5.59 ± 1.6, P < 0.001] and PNI [39 (20.4–51) versus 41 (23–52.2), P = 0.005] was significantly lower and CAR [2.03 (0.28–34.65) versus 1.28 (0.12–37.1), P = 0.041] was higher in sarcopenic ESRD group than non-sarcopenic ESRD group (Table 1). In the correlation analysis, PMI was positively correlated with PNI (r = 0.246, P = 0.002), no correlated with CAR (r = −0.061, P = 0.445). In the follow-up, 67 waitlisted patients had been transplanted. In the five-year survival analysis, the non-sarcopenic transplant group [95% CI: 4.612–5.123 versus 95% CI: 2.721–5.413, P = 0.001] had better survival than sarcopenic transplant group (Figure 1). Mortality rates were similar in both sarcopenic transplant group and non-sarcopenic-non-transplant group. Multivariate regression analysis showed that sarcopenia (HR: 10.277, 95% CI: 3.912–27.000, P < 0.001), not having a transplant (HR: 3.949, 95% CI: 1.301–11.993, P = 0.015), low PNI (HR: 3.532, 95% CI: 1.303–9.574, P = 0.013) and duration of renal replacement therapy (HR: 1.009, 95% CI: 1.002–1.015, P = 0.008) were independent risk factors for mortality in all ESRD group. CONCLUSION In this study we observed that sarcopenia, as defined by low muscle mass, is almost seen five times more frequent in ESRD patients than controls and positively correlated with PNI. Sarcopenia is an independent risk factor for mortality in waitlisted patients.

Abdominal lean muscle is associated with lower mortality among kidney waitlist candidates

Abdominal computed tomography measurements of body composition and waitlist mortality in kidney transplant candidates

Low skeletal muscle mass is associated with mortality in kidney transplant recipients

Sarcopenia is associated with survival in patients awaiting kidney transplant

A Statistical Prediction Model for Survival after Kidney Transplantation from Deceased Donors

Low muscle mass and early hospital readmission post-kidney transplantation

Computed Tomography-Assessed Sarcopenia Predicts Mortality in Kidney Transplant Candidates.

Pre-transplant morphometry by computed tomography scan and post-transplant dialysis risk in overweight or obese kidney transplant recipients

Surgical complications and graft survival in kidney transplant recipients according to CT-scans evaluation

MO956: Sarcopenia Predicts Mortality in Renal Transplant Candidates

Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value

Impact of Muscle Mass on Survival of Patients with Hepatocellular Carcinoma after Liver Transplantation Beyond the Milan Criteria

Low Muscle Mass by Pre-Procedural Computed Tomography is Associated with Worse Short-Term Outcomes in Transcatheter Aortic Valve Replacement Recipients

Use of Skeletal Muscle Index as a Predictor of Wait‐List Mortality in Patients With End‐Stage Liver Disease

Myosteatosis: an underrecognized risk factor for mortality in non-dialysis chronic kidney disease patients

Assessing Patients beyond the Simple Optics of BMI: The Concomitant Role of Sarcopenia and BMI in Predicting Kidney Transplant Outcomes

Skeletal Muscle Index as a Prognostic Marker for Kidney Transplantation in Older Patients

Association of the psoas muscle index with the survival of patients on a waiting list for lung transplantation: a Japanese single-institution study

Presence of Sarcopenia before Kidney Transplantation Is Associated with Poor Outcomes

Sarcopenia as a predictor of mortality in kidney transplant recipients: A 5-year prospective cohort study with propensity score matching

Intramuscular and abdominal fat measured by computed tomography and mortality of hemodialysis patients